Aimmune Therapeutics Inc (AIMT) Given Consensus Recommendation of “Buy” by Analysts

Share on StockTwits

Aimmune Therapeutics Inc (NASDAQ:AIMT) has been given an average recommendation of “Buy” by the twelve ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $52.78.

A number of analysts have commented on the stock. BidaskClub upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 7th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. ValuEngine lowered shares of Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 7th. Credit Suisse Group set a $40.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Monday, August 13th. Finally, Stifel Nicolaus assumed coverage on shares of Aimmune Therapeutics in a research note on Thursday, September 13th. They set a “hold” rating and a $33.00 price target for the company.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tiverton Asset Management LLC bought a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth $145,000. Xact Kapitalforvaltning AB bought a new stake in shares of Aimmune Therapeutics in the 1st quarter worth $207,000. Ardsley Advisory Partners bought a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth $202,000. Atria Investments LLC bought a new stake in shares of Aimmune Therapeutics in the 3rd quarter worth $213,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Aimmune Therapeutics in the 1st quarter worth $262,000. Hedge funds and other institutional investors own 78.15% of the company’s stock.

AIMT stock traded up $1.20 during midday trading on Monday, reaching $26.37. 407,218 shares of the company’s stock traded hands, compared to its average volume of 638,498. The firm has a market capitalization of $1.60 billion, a PE ratio of -10.10 and a beta of -0.26. Aimmune Therapeutics has a 52 week low of $24.56 and a 52 week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.05). Research analysts anticipate that Aimmune Therapeutics will post -3.63 EPS for the current year.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Further Reading: Cash Flow

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jury.Online Token  Achieves Market Capitalization of $425,799.00
Jury.Online Token Achieves Market Capitalization of $425,799.00
Aimmune Therapeutics Inc  Given Consensus Recommendation of “Buy” by Analysts
Aimmune Therapeutics Inc Given Consensus Recommendation of “Buy” by Analysts
Echostar Co.  Given Average Recommendation of “Hold” by Analysts
Echostar Co. Given Average Recommendation of “Hold” by Analysts
Hive Project  Reaches Market Cap of $9.61 Million
Hive Project Reaches Market Cap of $9.61 Million
Zacks: Sears Holdings Corp  Receives Consensus Recommendation of “Strong Sell” from Brokerages
Zacks: Sears Holdings Corp Receives Consensus Recommendation of “Strong Sell” from Brokerages
Critical Comparison: Infinity Property and Casualty  vs. Hartford Financial Services Group
Critical Comparison: Infinity Property and Casualty vs. Hartford Financial Services Group


Leave a Reply

© 2006-2018 Ticker Report. Google+.